# Cipla and Alkem Laboratories in final lap to buy SMT

Drugmakers Cipla and Alkem Laboratories are frontrunners to acquire a controlling stake in Sahajanand Medical Technologies (SMT), India's largest cardiac stent maker. The deal values SMT at Rs 3,500-4,000 crore.

- Type: Acquisition
- Announced: 2024-10-16
- Where: India
- Value: $420.0M (35.0B INR)
- Status: rumored
- Products: cardiac stents, drug-eluting stents
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Sahajanand Medical Technologies](https://endata.com/companies/27858.md) (target)
- [Cipla](https://endata.com/companies/47273.md) (acquirer)
- [Alkem Laboratories](https://endata.com/companies/74928.md) (acquirer)

## Sources

- [m.economictimes.com](https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-alkem-laboratories-in-final-lap-to-buy-smt/amp_articleshow/114261510.cms), 2024-10-15: "Drugmakers Cipla and Alkem Laboratories have emerged as the frontrunners to acquire a controlling stake in Sahajanand Medical Technologies (SMT), India's largest cardiac stent maker."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.